Working… Menu

The Application of Extremely Low Level Magnetic Fields as Adjunctive Treatment for Type II Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00982293
Recruitment Status : Terminated (Difficulty in Recruitment)
First Posted : September 23, 2009
Last Update Posted : May 5, 2011
Information provided by:
pico-tesla Magnetic Therapies, LLC

Brief Summary:
The purpose of this study is to see if using a device called the Resonator, that puts out very low level electromagnetic fields, effects blood glucose and A1c levels in people with Type 2 Diabetes.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Device: Resonator device Device: Resonator device - sham Phase 2

Detailed Description:
The purpose of this pilot study is to determine whether application of magnetic fields generated by the Resonator TM, as an adjunctive therapy to oral medications results in statistically significant reductions in fasting blood glucose levels, post prandial glucose levels and hemoglobin A1c levels. The study will also investigate any induced changes in serum lipids.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 165 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Official Title: A Randomized, Double Blind, Placebo Controlled Study of the Application of Magnetic Fields Using the Resonator in Adjunctive Management of Type 2 Diabetes Mellitus, Pilot Study II
Study Start Date : September 2009
Estimated Primary Completion Date : May 2011
Actual Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Active fields Device: Resonator device
Low level electromagnetic fields for whole body immersion, 3 times weekly for 13 weeks (39) sessions of approximately 11/2 hours each.

Sham Comparator: Inactive device
Placebo treated group, will receive the 3 times weekly for 13 weeks (39) sessions, however, the device will not be "on".
Device: Resonator device - sham
Treatment, 3 times weekly for 13 weeks (39) sessions - device will not be "on"

Primary Outcome Measures :
  1. The primary outcome measure is the improvement in Subject's hemoglobin A1c level after 13 weeks of treatment compared to baseline. [ Time Frame: baseline, end of treatment (13 weeks) and 3 months post treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Current diagnosis of Type 2 Diabetes Mellitus with a hemoglobin A1c level above 7.5%, despite management of diabetes with diet and/or medication.
  • Subject currently performs routine finger stick blood sugar testing as part of his or her current diabetes disease management regimen.
  • Subject is ambulatory
  • Subject is on stable oral medication regimen without significant side effects for at least three (3) months (stable insulin regimen NOT permissible); willingness and ability to maintain the stable oral medication regimen throughout the course of the study. If on agents suspected of contributing to hyperglycemia(see list below), subject must have been on a stable dose of this(these) agent(s) for 6 months prior to study initiation.
  • Hemoglobin A1c levels within a 0.8 % range of patient mean A1c level for the last two documented determinations, that must be within 2 years of the baseline testing date.
  • Willingness to test finger stick blood sugars according to prescribed protocol.
  • Willingness to have lab test blood draws performed according to prescribed protocol
  • Willingness to maintain stable diet and activity regimen for the duration of the study.
  • Willing and able to abstain from partaking in any non-essential (not physician ordered) existing or new treatments to improve serum blood sugar levels
  • Willing and able to abstain from all medications that could affect diabetes mellitus and/or any of its associated symptoms for the duration of the study
  • Adequate contraceptive measures for females subjects
  • Any ethnic background

Exclusion Criteria:

  • Change in medical regimen within 3 months prior to initiation of study.
  • Any signs of type 1 diabetes mellitus (including any history of ketoacidosis or new requirement for insulin therapy within the 6 month period prior to study initiation).
  • Active significant infectious process within 3 weeks of study initiation causing wide fluctuations in finger stick blood sugar level
  • Change in BMI of greater than 6 % within a 3 month period prior to study initiation
  • Any planned revascularization procedure.
  • Symptomatic congestive heart failure.
  • Leg or foot ulceration or open wounds
  • Gangrene.
  • History of intermittent claudication
  • Hemodialysis
  • Currently being treated for malignancy
  • Currently being treated with oral or intravenous catabolic steroids
  • Reported consumption of more than 14 alcoholic drinks per week.
  • Pregnant, breast feeding, or planning pregnancy prior to the end of participation
  • Developmental disability or cognitive impairment that would make it difficult for the subject to partake in the clinical study, including adequate comprehension of the informed consent form and ability to record the necessary measurements
  • Uncontrolled hypertension
  • Uncontrolled atrial fibrillation or other uncontrolled arrythmias, e.g. tachycardia, bradycardia
  • Uncontrolled seizure disorder
  • Uncontrolled, unstable, or untreated medical conditions which may significantly impact the subject's health or ability to complete the entire study, in the opinion of the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00982293

Layout table for location information
United States, Colorado
pico-tesla Magnetic Therapies
Littleton, Colorado, United States, 80120
Sponsors and Collaborators
pico-tesla Magnetic Therapies, LLC
Layout table for additonal information
Responsible Party: Allen S. Braswell CEO, pico-tesla Magnetic Therapies, LLC Identifier: NCT00982293    
Other Study ID Numbers: 09109-01
First Posted: September 23, 2009    Key Record Dates
Last Update Posted: May 5, 2011
Last Verified: May 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases